|
Volumn 6, Issue 10, 2000, Pages 3801-3802
|
Innovations in Phase 1 trial design: Where do we go next?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
INTERCALATING AGENT;
LEDOXANTRONE;
ANTINEOPLASTIC ACTIVITY;
CANCER RESEARCH;
CANCER THERAPY;
CLINICAL TRIAL;
DOSE RESPONSE;
DRUG SAFETY;
HUMAN;
METHODOLOGY;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
REVIEW;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE I;
HUMANS;
MAXIMUM TOLERATED DOSE;
NEOPLASMS;
|
EID: 0033760533
PISSN: 10780432
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (12)
|
References (15)
|